Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHY-ONC6 in Advanced or Metastatic Solid Tumors
NCT07705334Phase 1Recruiting
- Sponsor
- SHY Therapeutics
- Start
- Jun 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHY-ONC6 in solid tumor, triple-negative breast cancer (TNBC), hormone receptor-positive breast cancer and 8 more, sponsored by SHY Therapeutics. Primary endpoints: Incidence of Dose-Limiting Toxicities, Adverse Events, and Serious Adverse Events, Maximum Tolerated Dose at Day 21 and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
SHY-ONC6
03
Conditions
solid tumortriple-negative breast cancer (TNBC)hormone receptor-positive breast cancercolon cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT07705334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07705334.